Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Protein Kinase C × Clear all
NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

IDEAYA Biosciences

Phase 1/2 Recruiting
336 enrolled
DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡